Comparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in mice

被引:39
作者
Li, Xia [1 ]
Risbrough, Victoria B. [1 ,4 ]
Cates-Gatto, Chelsea [2 ]
Kaczanowska, Katarzyna [3 ]
Finn, M. G. [3 ]
Roberts, Amanda J. [2 ]
Markou, Athina [1 ]
机构
[1] Univ Calif San Diego, Sch Med, Dept Psychiat, La Jolla, CA 92093 USA
[2] Scripps Res Inst, Mol & Integrat Neurosci Dept, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA
[4] Vet Affairs Ctr Excellence Stress & Mental Hlth, La Jolla, CA USA
基金
美国国家卫生研究院;
关键词
GABA(B) receptor; Positive allosteric modulator; Anxiety; Learning; Memory; GAMMA-AMINOBUTYRIC-ACID; VOGEL CONFLICT TEST; ELEVATED PLUS-MAZE; ALLOSTERIC MODULATOR; ANIMAL-MODELS; MOTIVATIONAL PROPERTIES; WORKING-MEMORY; SPATIAL MEMORY; WATER MAZE; GS39783;
D O I
10.1016/j.neuropharm.2013.01.018
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
gamma-Arninobutyric acid B (GABA(B)) receptor activation is a potential therapeutic approach for the treatment of drug addiction, pain, anxiety, and depression. However, full agonists of this receptor induce side-effects, such as sedation, muscle relaxation, tolerance, and cognitive disruption. Positive allosteric modulators (PAMs) of the GABA(B) receptor may have similar therapeutic effects as agonists with superior side-effect profiles. The present study behaviorally characterized N-([1R,2R,4S]-bicyclo[2.2.1]hept-2-yl)-2-methyl-5-(4-[trifluoromethyl]phenyl)-4-pyrimidinamine (BHF177), a GABA(B) receptor PAM, in mouse models of anxiety-like behavior, learning and memory. In addition, the effects of BHF177 were compared with the agonist baclofen. Unlike the anxiolytic chlordiazepoxide, baclofen (0.5, 1.5, and 2.5 mg/kg, intraperitoneally) and BHF177 (10, 20, and 40 mg/kg, orally) had no effect on anxiety-like behavior in the elevated plus maze, light/dark box, or Vogel conflict test. Baclofen increased punished drinking in the Vogel conflict test, but this effect may be attributable to the analgesic actions of baclofen. At the highest dose tested (2.5 mg/kg), baclofen-treated mice exhibited sedation-like effects (i.e., reduced locomotor activity) across many of the tests, whereas BHF177-treated mice exhibited no sedation-like effects. BHF177 exhibited pro-convulsion properties only in mice, but not in rats, indicating that this effect may be species-specific. At doses that were not sedative or pro-convulsant, baclofen and BHF177 had no selective effects on fear memory retrieval in contextual and cued fear conditioning or spatial learning and memory in the Barnes maze. These data suggest that BHF177 has little sedative activity, no anxiolytic-like profile, and minimal impairment of learning and memory in mice. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:156 / 167
页数:12
相关论文
共 83 条
[1]  
AGMO A, 1991, N-S ARCH PHARMACOL, V344, P314
[2]   HANDLING HISTORY OF RATS MODIFIES BEHAVIORAL-EFFECTS OF DRUGS IN THE ELEVATED PLUS-MAZE TEST OF ANXIETY [J].
ANDREWS, N ;
FILE, SE .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 235 (01) :109-112
[3]   ANTICONVULSANT-LIKE ACTIONS OF BACLOFEN IN THE RAT HIPPOCAMPAL SLICE [J].
AULT, B ;
NADLER, JV .
BRITISH JOURNAL OF PHARMACOLOGY, 1983, 78 (04) :701-708
[4]   Baclofen analgesia: Involvement of the GABAergic system [J].
Balerio, GN ;
Rubio, MC .
PHARMACOLOGICAL RESEARCH, 2002, 46 (03) :281-286
[5]   γ-aminobutyric acid type B receptor splice variant proteins GBR1a and GBR1b are both associated with GBR2 in situ and display differential regional and subcellular distribution [J].
Benke, D ;
Honer, M ;
Michel, C ;
Bettler, B ;
Mohler, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (38) :27323-27330
[6]   Molecular structure and physiological functions of GABAB receptors [J].
Bettler, B ;
Kaupmann, K ;
Mosbacher, J ;
Gassmann, M .
PHYSIOLOGICAL REVIEWS, 2004, 84 (03) :835-867
[7]   Molecular diversity, trafficking and subcellular localization of GABAB receptors [J].
Bettler, Bernhard ;
Tiao, Jim Yu-Hsiang .
PHARMACOLOGY & THERAPEUTICS, 2006, 110 (03) :533-543
[8]   ELECTROPHYSIOLOGY OF GABAA AND GABAB RECEPTOR SUBTYPES [J].
BORMANN, J .
TRENDS IN NEUROSCIENCES, 1988, 11 (03) :112-116
[9]   Six decades of GABA [J].
Bowery, N ;
Enna, SJ ;
Olsen, RW .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (08) :1477-1478
[10]   GABAB RECEPTORS AND THEIR SIGNIFICANCE IN MAMMALIAN PHARMACOLOGY [J].
BOWERY, N .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1989, 10 (10) :401-407